THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, June 04, 2021
Excision BioTherapeutics announced the appointment of infectious disease specialist and clinical scientist Sumathi Sivapalasingam, M.D., to Head of Translational Medicine.
FREMONT, CA: Excision BioTherapeutics (Excision), a top developer of potentially curative CRISPR anti-viral therapies to improve patient lives, recently announced infectious disease specialist and clinical scientist Sumathi Sivapalasingam, M.D., to the position of Head of Translational Medicine.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"Dr. Sivapalasingams extensive experience as a clinical leader and her proficiency in integrating discovery research and translational medicine into transformational medicines will prove to be invaluable as we look forward to initiating the Companys first ever clinical trial of EBT-101 for HIV," said Daniel Dornbusch, Chief Executive Officer of Excision. "We are thrilled to have such an experienced infectious disease clinician join our team as we continue to advance our pipeline of CRISPR-based therapies for viral infectious diseases."
Dr. Sivapalasingam previously worked at Regeneron Pharmaceuticals as a Senior Director in Early Clinical Development and Experimental Sciences, where she was accountable for delivering and implementing pipeline assets from clinical candidate selection to the completion of late-stage clinical trials and approval. She was the clinical leader across several therapeutic areas, particularly infectious diseases, incorporating discovery research and translational medicine to improve the development of transformational drugs in this role. Dr. Sivapalasingam was the medical lead for the clinical development of Inmazeb, the first-ever approved treatment for Zaire ebolavirus infection in adults and children. She recently led many therapeutic trials early in the Covid-19 pandemic, including some with REGEN-COV, an investigational combination antibody treatment that gained Emergency Use Authorization to diagnose Covid-19 outpatients. She also worked for the Centers for Disease Control and Prevention in the Foodborne and Diarrheal Diseases Branch as an Epidemic Intelligence Service Officer. Dr. Sivapalasingam received her B.S. in Physics from Swarthmore College and her M.D. from Yeshiva University's Albert Einstein College of Medicine.
"Excisions CRISPR gene editing platform potentially enables therapeutics to be safely administered to patients through precise targeting and viral genome deactivation with a very low off-target effect probability," said Dr. Sivapalasingam. "It has proven to be an effective functional cure for HIV in animals in preclinical studies. It is an exciting opportunity to be joining an innovative company with the potential to transform the treatment of infectious diseases for patients globally. I look forward to working with the Company to advance its preclinical pipeline assets into the clinic and beyond."
More in News